Literature DB >> 8687193

Apolipoprotein E and cognitive change in an elderly population.

B T Hyman1, T Gomez-Isla, M Briggs, H Chung, S Nichols, F Kohout, R Wallace.   

Abstract

The apolipoprotein E (apoE) epsilon 4 allele is overrepresented, and the apoE epsilon 2 allele underrepresented, in Alzheimer's disease. To assess the risk of cognitive impairment in individuals with these genotypes in the general population, we studied a population-based sample of 1,899 individuals 65 years and older as a follow-up to the Iowa 65+ Rural Health Study. Multiple regression and logistic regression analyses demonstrated significant effects of apoE epsilon 4 and apoE epsilon 2 in predicting performance on a delayed recall task over a 4- to 7-year period. The magnitude of this effect was, however, fairly modest, with odds ratios for developing impairment of approximately 1.37 (95% confidence interval: 1.007, 1.850; p = 0.045) for apoE epsilon 4 and 0.53 (95% confidence interval: 0.368, 0.777; p = 0.001) for apoE epsilon 2. These effects were more pronounced in women than men. Importantly, 85% of elderly apoE E4/4 individuals (average age, 81) scored in the unimpaired range on a screening mental status test. Thus, many individuals reach old age without cognitive impair- ment despite inheritance of one or two apoE epsilon 4 alleles. This suggests that apoE genotyping will have limited utility as a diagnostic or prognostic indicator of cognitive decline in individuals.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8687193     DOI: 10.1002/ana.410400111

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  47 in total

Review 1.  The endosomal-lysosomal system of neurons in Alzheimer's disease pathogenesis: a review.

Authors:  R A Nixon; A M Cataldo; P M Mathews
Journal:  Neurochem Res       Date:  2000-10       Impact factor: 3.996

2.  Sex differences in the association of the apolipoprotein E epsilon 4 allele with incidence of dementia, cognitive impairment, and decline.

Authors:  May A Beydoun; Adel Boueiz; Marwan S Abougergi; Melissa H Kitner-Triolo; Hind A Beydoun; Susan M Resnick; Richard O'Brien; Alan B Zonderman
Journal:  Neurobiol Aging       Date:  2010-07-08       Impact factor: 4.673

3.  Latent structure and factorial invariance of a neuropsychological test battery for the study of preclinical Alzheimer's disease.

Authors:  N Maritza Dowling; Bruce Hermann; Asenath La Rue; Mark A Sager
Journal:  Neuropsychology       Date:  2010-11       Impact factor: 3.295

4.  Cognitive functions in low-grade gliomas: disease and treatment effects.

Authors:  Denise D Correa; Lisa M DeAngelis; Weiji Shi; Howard T Thaler; Michael Lin; Lauren E Abrey
Journal:  J Neurooncol       Date:  2006-07-19       Impact factor: 4.130

Review 5.  Protective actions of sex steroid hormones in Alzheimer's disease.

Authors:  Christian J Pike; Jenna C Carroll; Emily R Rosario; Anna M Barron
Journal:  Front Neuroendocrinol       Date:  2009-05-07       Impact factor: 8.606

6.  Apolipoprotein E ε2 and functional decline in amnestic mild cognitive impairment and Alzheimer disease.

Authors:  Aaron Bonner-Jackson; Ozioma Okonkwo; Geoffrey Tremont
Journal:  Am J Geriatr Psychiatry       Date:  2012-07       Impact factor: 4.105

7.  Clinical rationale of genetic testing in dementia.

Authors:  G B Frisoni; M Trabucchi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-03       Impact factor: 10.154

8.  Association Between APOE Alleles and Change of Neuropsychological Tests in the Long Life Family Study.

Authors:  Mengtian Du; Stacy L Andersen; Nicole Schupf; Mary F Feitosa; Megan S Barker; Thomas T Perls; Paola Sebastiani
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

9.  Apolipoprotein E4 is only a weak predictor of dementia and cognitive decline in the general population.

Authors:  A G Yip; C Brayne; D Easton; D C Rubinsztein
Journal:  J Med Genet       Date:  2002-09       Impact factor: 6.318

10.  Cognitive impairment in elderly women: the relative importance of selected genes, lifestyle factors, and comorbidities.

Authors:  Henrik Berg Rasmussen; Yu Z Bagger; László B Tankó; Gerong Qin; Claus Christiansen; Thomas Werge
Journal:  Neuropsychiatr Dis Treat       Date:  2006-06       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.